Vallon Pharmaceuticals, Inc. VLON
We take great care to ensure that the data presented and summarized in this overview for Vallon Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VLON
Top Purchases
Top Sells
About VLON
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Insider Transactions at VLON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 21
2023
|
Albert Agro Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
172,189
+50.0%
|
-
|
|
Apr 21
2023
|
Walter Marc Hertz Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
385,510
+50.0%
|
-
|
|
Apr 21
2023
|
Vipin Chaturvedi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
172,189
+50.0%
|
-
|
|
Dec 13
2022
|
Marella Thorell Director |
SELL
Other acquisition or disposition
|
Direct |
28,517
-75.0%
|
-
|
|
Jul 01
2022
|
Marella Thorell Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,023
+50.0%
|
-
|
|
Jun 04
2021
|
Leanne M. Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,508
+19.44%
|
$6,032
$4.08 P/Share
|
|
Jun 03
2021
|
Leanne M. Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,085
+18.62%
|
$4,340
$4.05 P/Share
|
|
Jun 02
2021
|
Leanne M. Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,657
+50.0%
|
$14,628
$4.0 P/Share
|
|
May 26
2021
|
Joseph E Payne Director |
BUY
Open market or private purchase
|
Direct |
6,800
+27.98%
|
$27,200
$4.5 P/Share
|
|
May 25
2021
|
Joseph E Payne Director |
BUY
Open market or private purchase
|
Direct |
10,700
+50.0%
|
$32,100
$3.85 P/Share
|
|
Feb 12
2021
|
David Charles Baker Director |
BUY
Open market or private purchase
|
Direct |
1,000
+10.16%
|
$8,000
$8.0 P/Share
|
|
Feb 12
2021
|
David Charles Baker Director |
BUY
Other acquisition or disposition
|
Direct |
7,843
+50.0%
|
$47,058
$6.4 P/Share
|
|
Feb 12
2021
|
Pharma Gmb H Salmon > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
47,063
+50.0%
|
$282,378
$6.4 P/Share
|
|
Feb 12
2021
|
Richard Ammer Director |
BUY
Other acquisition or disposition
|
Indirect |
47,063
+50.0%
|
$282,378
$6.4 P/Share
|